Peter Greenleaf
Chief Executive Officer
Replay available
Aurinia Pharmaceuticals Inc (AUPH) Q2 2025 Earnings Call
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Q2 2025 earnings conference call, held 2025-07-31. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Greg Keenan
Chief Medical Officer
Stacy Koo
Analyst, TD Cowen
Maury Raycroft
Analyst, Jefferies
Joe Schwartz
Analyst, Leerink Partners
Arthur He
Analyst, H.C. Wainwright
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Aurinia Pharmaceuticals Inc.
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.096 Good morning, and welcome to ARINIA's ARIT Intercept Phase 1 Study Results Conference 00:00:05.096 -- 00:00:10.782 Call. Please be advised that a Q&A session will follow ARINIA's prepared remarks. 00:00:10.782 -- 00:00:14.786 You may be placed at the question queue at any time by pressing star 1 on your telephone 00:00:14.786 -- 00:00:20.051 keypad, and we ask you please limit yourselves to one question and one follow-up. 00:00:20.051 -- 00:00:24.856 I will now turn the call over to Peter Greenleaf, Chief Executive Officer of ARINIA. 00:00:24.856 -- 00:00:26.777 Please go ahead, sir. 00:00:26.777 -- 00:00:31.656 Good morning. Thank you all for joining us to discuss the results from our ARIT Intercept 00:00:31.656 -- 00:00:37.023 Phase 1 Single Ascending Dose Study. ARIT Intercept has been previously referred 00:00:37.023 -- 00:00:39.727 to as AUR 200. 00:00:39.727 -- 00:00:44.513 Joining me on the call today are Dr. Greg Keenan, our Chief Medical Officer, and Joe 00:00:44.513 -- 00:00:48.095 Miller, our Chief Financial Officer. 00:00:48.298 -- 00:00:52.864 Before beginning our discussion, I'd like to direct your attention to slide two, which 00:00:52.864 -- 00:00:57.628 contains important information regarding forward-looking statements. 00:00:57.676 -- 00:01:01.081 With that introduction, let me now turn the call over to Dr. 00:01:01.081 -- 00:01:06.048 Greg Keenan to walk you through the R-Tintercept Phase 1 study results. 00:01:06.048 -- 00:01:07.851 Greg? 00:01:07.851 -- 00:01:13.720 Thank you, Peter. It's a pleasure speaking with you today about R-Tintercept 00:01:13.720 -- 00:01:18.487 and the results of our Phase 1 single ascending dose study. 00:01:18.487 -- 00:01:21.932 R-Tintercept is a dual BAP April inhibitor. 00:01:21....